What's Behind Gilead Sciences' Lackluster Q3 Earnings Results
Has Gilead Sciences (NASDAQ: GILD) really turned the corner after several years of sinking revenue and earnings? That was the question for investors as the big biotech prepared to provide an update on its third-quarter performance.
Gilead announced its Q3 results after the market closed on Thursday. And the answer to the big question appears to be a shaky "yes" -- even though Gilead's performance in the quarter was lackluster overall.
Image source: Getty Images.
Source Fool.com
